 | • レポートコード：MRC2Q12-19400 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、118ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、ロフルミラストのグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 ロフルミラストのアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 ロフルミラストの中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 ロフルミラストのヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までのロフルミラストの生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別のロフルミラストの売上および2028年までの予測に焦点を当てています。 ロフルミラストのグローバル主要企業には、Alkem Laboratories、Astra Zeneca、Beltapharm Spa、Breckenridge Pharma、Hetero Drugs、KMS Health Center、Micro Labs、MS Pharma、MSN Laboratories、Viatris、Orchid Pharma、Orifarm Group、Precise Group、Takeda Pharmaceutical、Torrent Groupなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 ロフルミラスト市場は、タイプとアプリケーションによって区分されます。世界のロフルミラスト市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 250Mcg、500Mcg 【アプリケーション別セグメント】 病院、クリニック、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - ロフルミラスト製品概要 - タイプ別市場（250Mcg、500Mcg） - アプリケーション別市場（病院、クリニック、その他） - 調査の目的 ・エグゼクティブサマリー - 世界のロフルミラスト販売量予測2017-2028 - 世界のロフルミラスト売上予測2017-2028 - ロフルミラストの地域別販売量 - ロフルミラストの地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別ロフルミラスト販売量 - 主要メーカー別ロフルミラスト売上 - 主要メーカー別ロフルミラスト価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（250Mcg、500Mcg） - ロフルミラストのタイプ別販売量 - ロフルミラストのタイプ別売上 - ロフルミラストのタイプ別価格 ・アプリケーション別市場規模（病院、クリニック、その他） - ロフルミラストのアプリケーション別販売量 - ロフルミラストのアプリケーション別売上 - ロフルミラストのアプリケーション別価格 ・北米市場 - 北米のロフルミラスト市場規模（タイプ別、アプリケーション別） - 主要国別のロフルミラスト市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパのロフルミラスト市場規模（タイプ別、アプリケーション別） - 主要国別のロフルミラスト市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋のロフルミラスト市場規模（タイプ別、アプリケーション別） - 主要国別のロフルミラスト市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米のロフルミラスト市場規模（タイプ別、アプリケーション別） - 主要国別のロフルミラスト市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカのロフルミラスト市場規模（タイプ別、アプリケーション別） - 主要国別のロフルミラスト市場規模（トルコ、サウジアラビア） ・企業情報 Alkem Laboratories、Astra Zeneca、Beltapharm Spa、Breckenridge Pharma、Hetero Drugs、KMS Health Center、Micro Labs、MS Pharma、MSN Laboratories、Viatris、Orchid Pharma、Orifarm Group、Precise Group、Takeda Pharmaceutical、Torrent Group ・産業チェーン及び販売チャネル分析 - ロフルミラストの産業チェーン分析 - ロフルミラストの原材料 - ロフルミラストの生産プロセス - ロフルミラストの販売及びマーケティング - ロフルミラストの主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - ロフルミラストの産業動向 - ロフルミラストのマーケットドライバー - ロフルミラストの課題 - ロフルミラストの阻害要因 ・主な調査結果 |
Novel COPD treatment drugs
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Roflumilast is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Roflumilast is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Roflumilast is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key manufacturers of Roflumilast include Alkem Laboratories, Astra Zeneca, Beltapharm Spa, Breckenridge Pharma, Hetero Drugs, KMS Health Center, Micro Labs, MS Pharma and MSN Laboratories, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers’ production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Roflumilast manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Roflumilast market. Further, it explains the major drivers and regional dynamics of the global Roflumilast market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Alkem Laboratories
Astra Zeneca
Beltapharm Spa
Breckenridge Pharma
Hetero Drugs
KMS Health Center
Micro Labs
MS Pharma
MSN Laboratories
Viatris
Orchid Pharma
Orifarm Group
Precise Group
Takeda Pharmaceutical
Torrent Group
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by dosage strength and by application segments based on sales, price, and value for the period 2017-2028.
Roflumilast Segment by Dosage Strength
250Mcg
500Mcg
Roflumilast Segment by Application
Hospital
Clinic
Other
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Roflumilast market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Roflumilast, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Roflumilast, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Roflumilast, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Roflumilast sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global Roflumilast market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for Roflumilast sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Alkem Laboratories, Astra Zeneca, Beltapharm Spa, Breckenridge Pharma, Hetero Drugs, KMS Health Center, Micro Labs, MS Pharma and MSN Laboratories, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Roflumilast in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Roflumilast manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by dosage strength, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by dosage strength, by application and by country, sales and revenue for each segment.
Chapter 8: Asia Pacific by dosage strength, by application and by country, sales and revenue for each segment.
Chapter 9: Latin America by dosage strength, by application and by country, sales and revenue for each segment.
Chapter 10: Middle East and Africa by dosage strength, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Roflumilast sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
1 Study Coverage
1.1 Roflumilast Product Introduction
1.2 Market by Dosage Strength
1.2.1 Global Roflumilast Market Size Growth Rate by Dosage Strength, 2017 VS 2021 VS 2028
1.2.2 250Mcg
1.2.3 500Mcg
1.3 Market by Application
1.3.1 Global Roflumilast Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Roflumilast Sales Estimates and Forecasts 2017-2028
2.2 Global Roflumilast Revenue Estimates and Forecasts 2017-2028
2.3 Global Roflumilast Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Roflumilast Sales by Region
2.4.1 Global Roflumilast Sales by Region (2017-2022)
2.4.2 Global Sales Roflumilast by Region (2023-2028)
2.5 Global Roflumilast Revenue by Region
2.5.1 Global Roflumilast Revenue by Region (2017-2022)
2.5.2 Global Roflumilast Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Roflumilast Sales by Manufacturers
3.1.1 Global Top Roflumilast Manufacturers by Sales (2017-2022)
3.1.2 Global Roflumilast Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Roflumilast in 2021
3.2 Global Roflumilast Revenue by Manufacturers
3.2.1 Global Roflumilast Revenue by Manufacturers (2017-2022)
3.2.2 Global Roflumilast Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Roflumilast Revenue in 2021
3.3 Global Roflumilast Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Roflumilast Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Roflumilast Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Dosage Strength
4.1 Global Roflumilast Sales by Dosage Strength
4.1.1 Global Roflumilast Historical Sales by Dosage Strength (2017-2022)
4.1.2 Global Roflumilast Forecasted Sales by Dosage Strength (2023-2028)
4.1.3 Global Roflumilast Sales Market Share by Dosage Strength (2017-2028)
4.2 Global Roflumilast Revenue by Dosage Strength
4.2.1 Global Roflumilast Historical Revenue by Dosage Strength (2017-2022)
4.2.2 Global Roflumilast Forecasted Revenue by Dosage Strength (2023-2028)
4.2.3 Global Roflumilast Revenue Market Share by Dosage Strength (2017-2028)
4.3 Global Roflumilast Price by Dosage Strength
4.3.1 Global Roflumilast Price by Dosage Strength (2017-2022)
4.3.2 Global Roflumilast Price Forecast by Dosage Strength (2023-2028)
5 Market Size by Application
5.1 Global Roflumilast Sales by Application
5.1.1 Global Roflumilast Historical Sales by Application (2017-2022)
5.1.2 Global Roflumilast Forecasted Sales by Application (2023-2028)
5.1.3 Global Roflumilast Sales Market Share by Application (2017-2028)
5.2 Global Roflumilast Revenue by Application
5.2.1 Global Roflumilast Historical Revenue by Application (2017-2022)
5.2.2 Global Roflumilast Forecasted Revenue by Application (2023-2028)
5.2.3 Global Roflumilast Revenue Market Share by Application (2017-2028)
5.3 Global Roflumilast Price by Application
5.3.1 Global Roflumilast Price by Application (2017-2022)
5.3.2 Global Roflumilast Price Forecast by Application (2023-2028)
6 North America
6.1 North America Roflumilast Market Size by Dosage Strength
6.1.1 North America Roflumilast Sales by Dosage Strength (2017-2028)
6.1.2 North America Roflumilast Revenue by Dosage Strength (2017-2028)
6.2 North America Roflumilast Market Size by Application
6.2.1 North America Roflumilast Sales by Application (2017-2028)
6.2.2 North America Roflumilast Revenue by Application (2017-2028)
6.3 North America Roflumilast Market Size by Country
6.3.1 North America Roflumilast Sales by Country (2017-2028)
6.3.2 North America Roflumilast Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Roflumilast Market Size by Dosage Strength
7.1.1 Europe Roflumilast Sales by Dosage Strength (2017-2028)
7.1.2 Europe Roflumilast Revenue by Dosage Strength (2017-2028)
7.2 Europe Roflumilast Market Size by Application
7.2.1 Europe Roflumilast Sales by Application (2017-2028)
7.2.2 Europe Roflumilast Revenue by Application (2017-2028)
7.3 Europe Roflumilast Market Size by Country
7.3.1 Europe Roflumilast Sales by Country (2017-2028)
7.3.2 Europe Roflumilast Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Roflumilast Market Size by Dosage Strength
8.1.1 Asia Pacific Roflumilast Sales by Dosage Strength (2017-2028)
8.1.2 Asia Pacific Roflumilast Revenue by Dosage Strength (2017-2028)
8.2 Asia Pacific Roflumilast Market Size by Application
8.2.1 Asia Pacific Roflumilast Sales by Application (2017-2028)
8.2.2 Asia Pacific Roflumilast Revenue by Application (2017-2028)
8.3 Asia Pacific Roflumilast Market Size by Region
8.3.1 Asia Pacific Roflumilast Sales by Region (2017-2028)
8.3.2 Asia Pacific Roflumilast Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Roflumilast Market Size by Dosage Strength
9.1.1 Latin America Roflumilast Sales by Dosage Strength (2017-2028)
9.1.2 Latin America Roflumilast Revenue by Dosage Strength (2017-2028)
9.2 Latin America Roflumilast Market Size by Application
9.2.1 Latin America Roflumilast Sales by Application (2017-2028)
9.2.2 Latin America Roflumilast Revenue by Application (2017-2028)
9.3 Latin America Roflumilast Market Size by Country
9.3.1 Latin America Roflumilast Sales by Country (2017-2028)
9.3.2 Latin America Roflumilast Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Roflumilast Market Size by Dosage Strength
10.1.1 Middle East and Africa Roflumilast Sales by Dosage Strength (2017-2028)
10.1.2 Middle East and Africa Roflumilast Revenue by Dosage Strength (2017-2028)
10.2 Middle East and Africa Roflumilast Market Size by Application
10.2.1 Middle East and Africa Roflumilast Sales by Application (2017-2028)
10.2.2 Middle East and Africa Roflumilast Revenue by Application (2017-2028)
10.3 Middle East and Africa Roflumilast Market Size by Country
10.3.1 Middle East and Africa Roflumilast Sales by Country (2017-2028)
10.3.2 Middle East and Africa Roflumilast Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Alkem Laboratories
11.1.1 Alkem Laboratories Corporation Information
11.1.2 Alkem Laboratories Overview
11.1.3 Alkem Laboratories Roflumilast Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Alkem Laboratories Roflumilast Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Alkem Laboratories Recent Developments
11.2 Astra Zeneca
11.2.1 Astra Zeneca Corporation Information
11.2.2 Astra Zeneca Overview
11.2.3 Astra Zeneca Roflumilast Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Astra Zeneca Roflumilast Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Astra Zeneca Recent Developments
11.3 Beltapharm Spa
11.3.1 Beltapharm Spa Corporation Information
11.3.2 Beltapharm Spa Overview
11.3.3 Beltapharm Spa Roflumilast Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Beltapharm Spa Roflumilast Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Beltapharm Spa Recent Developments
11.4 Breckenridge Pharma
11.4.1 Breckenridge Pharma Corporation Information
11.4.2 Breckenridge Pharma Overview
11.4.3 Breckenridge Pharma Roflumilast Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Breckenridge Pharma Roflumilast Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Breckenridge Pharma Recent Developments
11.5 Hetero Drugs
11.5.1 Hetero Drugs Corporation Information
11.5.2 Hetero Drugs Overview
11.5.3 Hetero Drugs Roflumilast Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Hetero Drugs Roflumilast Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Hetero Drugs Recent Developments
11.6 KMS Health Center
11.6.1 KMS Health Center Corporation Information
11.6.2 KMS Health Center Overview
11.6.3 KMS Health Center Roflumilast Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 KMS Health Center Roflumilast Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 KMS Health Center Recent Developments
11.7 Micro Labs
11.7.1 Micro Labs Corporation Information
11.7.2 Micro Labs Overview
11.7.3 Micro Labs Roflumilast Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Micro Labs Roflumilast Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Micro Labs Recent Developments
11.8 MS Pharma
11.8.1 MS Pharma Corporation Information
11.8.2 MS Pharma Overview
11.8.3 MS Pharma Roflumilast Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 MS Pharma Roflumilast Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 MS Pharma Recent Developments
11.9 MSN Laboratories
11.9.1 MSN Laboratories Corporation Information
11.9.2 MSN Laboratories Overview
11.9.3 MSN Laboratories Roflumilast Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 MSN Laboratories Roflumilast Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 MSN Laboratories Recent Developments
11.10 Viatris
11.10.1 Viatris Corporation Information
11.10.2 Viatris Overview
11.10.3 Viatris Roflumilast Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Viatris Roflumilast Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Viatris Recent Developments
11.11 Orchid Pharma
11.11.1 Orchid Pharma Corporation Information
11.11.2 Orchid Pharma Overview
11.11.3 Orchid Pharma Roflumilast Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Orchid Pharma Roflumilast Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Orchid Pharma Recent Developments
11.12 Orifarm Group
11.12.1 Orifarm Group Corporation Information
11.12.2 Orifarm Group Overview
11.12.3 Orifarm Group Roflumilast Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Orifarm Group Roflumilast Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Orifarm Group Recent Developments
11.13 Precise Group
11.13.1 Precise Group Corporation Information
11.13.2 Precise Group Overview
11.13.3 Precise Group Roflumilast Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Precise Group Roflumilast Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Precise Group Recent Developments
11.14 Takeda Pharmaceutical
11.14.1 Takeda Pharmaceutical Corporation Information
11.14.2 Takeda Pharmaceutical Overview
11.14.3 Takeda Pharmaceutical Roflumilast Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Takeda Pharmaceutical Roflumilast Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Takeda Pharmaceutical Recent Developments
11.15 Torrent Group
11.15.1 Torrent Group Corporation Information
11.15.2 Torrent Group Overview
11.15.3 Torrent Group Roflumilast Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Torrent Group Roflumilast Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Torrent Group Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Roflumilast Industry Chain Analysis
12.2 Roflumilast Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Roflumilast Production Mode & Process
12.4 Roflumilast Sales and Marketing
12.4.1 Roflumilast Sales Channels
12.4.2 Roflumilast Distributors
12.5 Roflumilast Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Roflumilast Industry Trends
13.2 Roflumilast Market Drivers
13.3 Roflumilast Market Challenges
13.4 Roflumilast Market Restraints
14 Key Findings in The Global Roflumilast Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer